The effectiveness of early administration of interleukin-17 blockers in the treatment of axial lesions in psoriatic arthritis

Pharmateca ◽  
2021 ◽  
Vol 14_2021 ◽  
pp. 22-26
Author(s):  
L.S. Kruglova Kruglova ◽  
N.O. Pereverzina Pereverzina ◽  
Keyword(s):  
Psoriatic Arthritis ◽  
Interleukin 17 ◽  
Early Administration

scholarly journals Spondyloarthritis: management algorithms and experience of target therapy

2019 ◽  
Vol 1 (18) ◽  
pp. 6-12
Author(s):  
A. R. Babaeva ◽  
E. V. Kalinina ◽  
M. S. Zvonorenko ◽  
E. V. Shcherbinina ◽  
I. V. Bramnik
Keyword(s):  
Psoriatic Arthritis ◽  
Ankylosing Spondylitis ◽  
Target Therapy ◽  
Current Data ◽  
Interleukin 17 ◽  
Basic Drug ◽  
Insufficient Response ◽  
Axial Spondylarthritis ◽  
Management Algorithms

The article presents current data on algorithms for managing patients with the most common forms of spondylarthritis — ankylosing spondylitis, axial spondylarthritis and psoriatic arthritis, based on existing national and European recommendations. The analysis of innovative approaches to the patho‑genetic therapy of spondyloarthritis with special attention to the inhibition of interleukin‑17 using the drug secukinumab. Along with the literature data, there is a clinical experience of using secukinumab in patients with ankylosing spondylitis, axial spondyloarthritis, and psoriatic arthritis. It has been shown that secukinumab can improve the quality of treatment and achieve clinical remission in patients with high disease activity and adverse prognostic factors. In connection with the high efficacy and safety of treatment, the feasibility of using secukinumab as a first‑line biological agent with insufficient response to a standard basic drug is discussed.

Candida infections in patients with psoriasis and psoriatic arthritis treated with interleukin-17 inhibitors and their practical management

2021 ◽  
Vol 156 (5) ◽  
Author(s):  
Carmen RODRÍGUEZ-CERDEIRA ◽  
José L. GONZÁLEZ-CESPÓN ◽  
Erick MARTÍNEZ-HERRERA ◽  
Miguel CARNERO-GREGORIO ◽  
Adriana LÓPEZ-BARCENAS ◽  
...  
Keyword(s):  
Psoriatic Arthritis ◽  
Interleukin 17 ◽  
Practical Management ◽  
Candida Infections

scholarly journals Paradoxical gastrointestinal effects of interleukin-17 blockers

2020 ◽  
Vol 79 (9) ◽  
pp. 1132-1138 ◽  
Author(s):  
Marine Fauny ◽  
David Moulin ◽  
Ferdinando D'Amico ◽  
Patrick Netter ◽  
Nadine Petitpain ◽  
...  
Keyword(s):  
Ulcerative Colitis ◽  
Monoclonal Antibody ◽  
Clinical Practice ◽  
Psoriatic Arthritis ◽  
Interleukin 17 ◽  
Disease Exacerbation ◽  
Disease Flare ◽  
Paradoxical Effects ◽  
Bowel Diseases ◽  
Inflammatory Bowel

Secukinumab, ixekizumab and brodalumab are monoclonal antibody therapies that inhibit interleukin (IL)-17 activity and are widely used for the treatment of psoriasis, psoriatic arthritis and ankylosing spondylitis. The promising efficacy results in dermatology and rheumatology prompted the evaluation of these drugs in Crohn’s disease and ulcerative colitis, but the onset of paradoxical events (disease exacerbation after treatment with a theoretically curative drug) prevented their approval in patients with inflammatory bowel diseases (IBDs). To date, the pathophysiological mechanisms underlying these paradoxical effects are not well defined, and there are no clear guidelines for the management of patients with disease flare or new IBD onset after anti-IL-17 drug therapy. In this review, we summarise the literature on putative mechanisms, the clinical digestive effects after therapy with IL-17 inhibitors and provide guidance for the management of these paradoxical effects in clinical practice.

Interleukin-17 inhibition in psoriatic arthritis

The Lancet ◽  
2015 ◽  
Vol 386 (9999) ◽  
pp. 1114-1116 ◽  
Author(s):  
Philip Helliwell ◽  
Laura Coates
Keyword(s):  
Psoriatic Arthritis ◽  
Interleukin 17

scholarly journals Interleukin-17+CD8+ T Cells Are Enriched in the Joints of Patients With Psoriatic Arthritis and Correlate With Disease Activity and Joint Damage Progression

2014 ◽  
Vol 66 (5) ◽  
pp. 1272-1281 ◽  
Author(s):  
Bina Menon ◽  
Nicola J. Gullick ◽  
Gina J. Walter ◽  
Megha Rajasekhar ◽  
Toby Garrood ◽  
...  
Keyword(s):  
T Cells ◽  
Psoriatic Arthritis ◽  
Disease Activity ◽  
Cd8 T Cells ◽  
Joint Damage ◽  
Interleukin 17 ◽  
Damage Progression

scholarly journals The efficacy of the interleukin 17 inhibitor ixekizumab in psoriatic arthritis: data from real clinical practice

2021 ◽  
Vol 15 (3) ◽  
pp. 86-90
Author(s):  
I. M. Marusenko ◽  
O. N. Sakovich
Keyword(s):  
Clinical Trial ◽  
Clinical Practice ◽  
Psoriatic Arthritis ◽  
Clinical Case ◽  
Interleukin 17 ◽  
Standard Methods ◽  
Skin Symptoms ◽  
The Republic ◽  
Drug Provision ◽  
Real Clinical Practice

The article describes the peculiarities of drug provision for patients with psoriatic arthritis (PsA) in the Republic of Karelia. We present a clinical case of effective treatment with interleukin 17 inhibitor ixekizumab (IXE) in a randomized clinical trial and real clinical practice in a patient with PsA. The distinctive feature of this case is the severity of PsA course that was not controlled by standard methods of therapy. IXE treatment was characterized by a rapid clinical improvement of both articular and skin symptoms and subsequent achievement of remission, which lasted for 3 years (on the therapy). The forced interruption of the treatment led to the relapse of the disease in a short amount of time. In 2 years IXE therapy was resumed; after 6 months of continuing treatment a stable remission of PsA was achieved. The patient is still in clinical remission (on therapy).

Sign in / Sign up

Export Citation Format

Share Document